Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mary B Callanan"'
Autor:
Antonin Bouroumeau, Lucile Bussot, Thierry Bonnefoix, Cyril Fournier, Caroline Chapusot, Olivier Casasnovas, Laurent Martin, Anne McLeer, Edwige Col, Laurence David‐Boudet, Christine Lefebvre, Caroline Algrin, Tatiana Raskovalova, Marie‐Christine Jacob, Claire Vettier, Simon Chevalier, Mary B Callanan, Rémy Gressin, Anouk Emadali, Hervé Sartelet
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 7, Iss 6, Pp 604-615 (2021)
Abstract Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will rel
Externí odkaz:
https://doaj.org/article/5db1d304fd2549028c3657336d17a691
Autor:
Rémy Gressin, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, Sylvain Carras, Emmanuelle Tchernonog, Anna Schmitt, Roch Houot, Caroline Dartigeas, Jean Michel Pignon, Selim Corm, Anne Banos, Christiane Mounier, Jehan Dupuis, Margaret Macro, Joel Fleury, Fabrice Jardin, Clementine Sarkozy, Ghandi Damaj, Pierre Feugier, Luc Matthieu Fornecker, Cecile Chabrot, Veronique Dorvaux, Krimo Bouadallah, Sandy Amorin, Reda Garidi, Laurent Voillat, Bertrand Joly, Philippe Solal Celigny, Nadine Morineau, Marie Pierre Moles, Hacene Zerazhi, Jean Fontan, Yazid Arkam, Magda Alexis, Vincent Delwail, Jean Pierre Vilque, Loic Ysebaert, Steven Le Gouill, Mary B. Callanan, for the Lymphoma Study Association
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total of 74 patients were enrol
Externí odkaz:
https://doaj.org/article/79f2a1ceb2cb45838a53d023cfec6ba8
Autor:
Benjamin Tournier, Romain Aucagne, Caroline Truntzer, Cyril Fournier, François Ghiringhelli, Caroline Chapusot, Laurent Martin, Anne Marie Bouvier, Sylvain Manfredi, Valérie Jooste, Mary B. Callanan, Côme Lepage
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 158
Stage II colon cancer (CC), although diagnosed early, accounts for 16% of CC deaths. Predictors of recurrence risk could mitigate this but are currently lacking. By using a DNA methylation-based clinical screening in real-world (n = 383) and in TCGA-
Autor:
Baptiste Dumetier, Camille Sauter, Azadeh Hajmirza, Baptiste Pernon, Romain Aucagne, Cyril Fournier, Céline Row, Fabien Guidez, Cédric Rossi, Côme Lepage, Laurent Delva, Mary B. Callanan
Publikováno v:
Biomedicines. 10(12)
The human genome is composed of unique DNA sequences that encode proteins and unique sequence noncoding RNAs that are essential for normal development and cellular differentiation. The human genome also contains over 50% of genome sequences that are
Autor:
Azadeh Hajmirza, Anouk Emadali, Arnaud Gauthier, Olivier Casasnovas, Rémy Gressin, Mary B. Callanan
Publikováno v:
Biomedicines, Vol 6, Iss 1, p 16 (2018)
NFκB (Nuclear Factor-κ-light-chain-enhancer of activated B cells) signaling elicits global transcriptional changes by activating cognate promoters and through genome-wide remodeling of cognate regulatory elements called “super enhancers”. BET (
Externí odkaz:
https://doaj.org/article/79ff9412be664cf0bfb0c724c493cd8f
Autor:
Antonin Bouroumeau, Lucile Bussot, Hervé Sartelet, Cyril Fournier, Patricia Betton-Fraisse, Edwige Col, Laurence David-Boudet, Anne McLeer, Christine Lefebvre, Tatiana Raskovalova, Marie-Christine Jacob, Claire Vettier, Simon Chevalier, Caroline Algrin, Sylvain Carras, Rémy Gressin, Mary B. Callanan, Thierry Bonnefoix, Anouk Emadali
Publikováno v:
HemaSphere
HemaSphere, Vol 5, Iss 7, p e598 (2021)
HemaSphere, Vol 5, Iss 7, p e598 (2021)
Publikováno v:
Revue Francophone des Laboratoires. 2018:28-33
Resume L’utilisation de donnees genomiques pour guider le traitement du patient atteint de cancer represente le principe de base de l’application de la medecine genomique en oncologie et en onco-hematologie. Il s’agit de proposer aux patients d
Autor:
Emeric Limagne, Lisa Nuttin, Marion Thibaudin, Elise Jacquin, Romain Aucagne, Marjorie Bon, Solène Revy, Robby Barnestein, Elise Ballot, Caroline Truntzer, Valentin Derangère, Jean-David Fumet, Charlène Latour, Cédric Rébé, Pierre-Simon Bellaye, Coureche-Guillaume Kaderbhaï, Aodrenn Spill, Bertrand Collin, Mary B. Callanan, Aurélie Lagrange, Laure Favier, Bruno Coudert, Laurent Arnould, Sylvain Ladoire, Bertrand Routy, Philippe Joubert, François Ghiringhelli
Publikováno v:
Cancer Cell. 40:136-152.e12
Autor:
Thomas Gastinne, Sylviane Ragot, Krimo Bouabdallah, David Chiron, Rory McCulloch, Céline Bossard, Cédric Rossi, Caroline Bodet-Milin, Emmanuelle Tchernonog, Simon Rule, Benoit Tessoulin, Guillaume Cartron, Nathalie Nadal, Steven Le Gouill, Olivier Casasnovas, Franck Morschhauser, Mary B. Callanan, Charles Herbaux
Publikováno v:
Blood. 137(7)
Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in
Autor:
Mary B. Callanan, Elizabeth Macintyre, Marie-Helene Delfau-Larue, Catherine Thieblemont, Lucie Oberic, Emmanuel Gyan, Krimo Bouabdallah, Rémy Gressin, Gandhi Damaj, Olivier Casasnovas, Vincent Ribrag, Samuel Griolet, Bénédicte Burlet, Benjamin Tournier, Sylviane Ragot, Caroline Bodet-Milin, Olivier Hermine, Steven Le Gouill
Publikováno v:
Blood. 136:12-13
INTRODUCTION : Minimal residual disease (MRD) has emerged as an important predictor of clinical outcome in patients with mantle cell lymphoma (MCL). Its use in everyday clinical practice, however, remains uncertain since standardized MRD monitoring s